THC Therapeutics, Inc. has announced the acquisition of The Headquarters Group, Inc., consolidating its position in the legal cannabis industry. The transaction, valued at approximately $11 million, was completed through the issuance of 11,007 thousand shares of Series D Preferred stock. This strategic move unites THC Therapeutics with The Headquarters Group, a company with over 60 years of combined experience in genetics, cultivation, extraction, and distribution, as well as specialty real estate and nutrients for cannabis growers. The acquisition includes companies with a combined revenue of $4.8 million and is intended to maximize efficiencies and generate significant revenue through a fully integrated vertical cannabis platform.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.